ClinicalTrials.gg
CompletedNCT03960658Updated Oct 14, 2026Results posted

Ketamine and Prolonged Exposure in PTSD

A Phase 1/2 interventional study of ketamine-enhanced prolonged exposure in Post-traumatic Stress Disorder, sponsored by Minneapolis Veterans Affairs Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Minneapolis Veterans Affairs Medical Center · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
1,316th of 1,491
12 · median 65
Started
2019
with 93 others
Phase 1/2
35 of 1,664
3 open now
Registered
935th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,316th largest by enrollment of the 1,491 interventional ones that give a count, is one of 94 that started in 2019, is one of 35 in phase 1/2, and was the 935th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This study aims at investigating the effectiveness of the drug, Ketamine, in combination with Prolonged Exposure (PE) therapy for people suffering from PTSD. Participation in the study includes Ketamine infusions, which occur once a week for three weeks. PE therapy sessions will be scheduled one day after each infusion, and may continue up to 12 weeks. After completely therapy, there will be two monthly follow-up assessment visits.

Read the detailed description

Study location: Minneapolis VA Medical Center

The study is an open-label interventional study designed to inform and strengthen the feasibility of protocol implementation on sub-anesthetic doses of intravenous Ketamine as augmenting strategy of standardized, manually-driven Prolonged Exposure therapy in PTSD.

Timeline: Eligible individuals can expect their participation to last up to 5 months. Compensation will be given for participation per session that is attended. Potential participants will be provided with information about the study and asked a series of questions to determine if they meet basic inclusion/exclusion criteria (e.g., indicators of current PTSD). They will be informed that the treatment involves multiple infusions of sedatives at subanesthetic doses followed by PE therapy. Those interested will be scheduled for an in-person, baseline session.

Voluntary informed consent will be obtained in accordance with local IRB approvals. During the baseline, all assessments, computer tasks, and information on treatment will be explained. Participants will also undergo a urine toxicology analysis during this session. Ketamine infusions and PE therapy appointments will be scheduled within two weeks of the baseline.

The day of the infusion, patients will arrive in the morning after an overnight fast of at least 8 hours. An IV will be placed in the non-dominant arm for medication administration. Vitals will be recorded throughout the entire medication treatment. Subjects will then receive IV infusion of 0.5mg/Kg of ketamine hydrochloride solution over 40 minutes. The dose of ketamine will be calculated by ideal body weight. Any altered sensory or dissociative effects will be measured before and after each infusion. Vitals will be monitored for another hour, until all side-effects have subsided. Participants are required not to drive or use heavy machinery until the following morning.

One day after the infusion, patients will come back for study assessments and Prolonged Exposure therapy with a VA psychologist. PE is an evidence-based psychotherapy for PTSD that is based on the Emotional Processing Theory of PTSD; the four components of PE are: 1) exposure to safe situations, objects, or people that cause distress and are avoided because they are trauma reminders (in vivo exposure), 2) revisiting and processing of the trauma memory (imaginal exposure), 3) psycho-education about trauma-related symptoms, and 4) breathing retraining. Session 1 includes the presentation of treatment rationale and program overview, information gathering, and breathing retraining. Session 2 includes education about common reactions to trauma, rationale for in vivo exposure, and construction of an in vivo exposure hierarchy. The hierarchy includes safe or low-risk activities and situations that were avoided because of their association with the trauma. Throughout the treatment, participants will be assigned homework to confront items on the hierarchy in a gradual fashion, working up to the most anxiety-arousing situations. During Session 3, the rationale for confronting the trauma memory in imagination is presented and initiation of imaginal exposure and processing is conducted. In this procedure, participants will be asked to close their eyes, visualize the trauma, and recount it aloud in the present tense for 45-60 min. The memory recounting will be repeated if necessary to allow total reliving of 45-60 min. The exposure will be audiotaped; participants will be instructed to listen daily to the tape. Sessions 4-10 will be conducted in a similar fashion: therapists review homework, conduct imaginal exposure to trauma memory for 30-45 min, discuss the imaginal exposure, and assigned in vivo and imaginal exposure homework. In the final session, participants summarize learning in treatment, discuss their progress, plans, and relapse prevention.

Upon PE completion, participants are asked to come back for 2 follow-up sessions over two months. Familiar study and PTSD assessments will be administered during this time.

03

Conditions studied

  • Post-traumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of chronic (minimum of three months) PTSD (Clinician-Administered PTSD Scale for -CAPS-5 score>33).
  2. Voluntarily eligible to participate in PE.
  3. Severity of PTSD symptoms defined by PCL-5>33.
  4. Psychotropic medications on stable doses (no dosing adjustments/changes for ≥4 weeks; ≥6 weeks for fluoxetine) prior to prior to beginning of the study.

Exclusion criteria

Exclusion Criteria:

  1. Unwillingness/unable to sign .
  2. Previous or current participation in trauma-exposed therapy and/or ketamine treatment.
  3. Evidence of mental retardation, pervasive developmental disorder and/or moderate/severe cognitive impairment ( scores ≤27).
  4. Any unstable medical or non-psychiatric CNS condition.
  5. Lifetime history of psychosis-related disorder, bipolar disorder I or II disorder, or any condition other than PTSD judged to be the primary presenting psychiatric diagnosis.
  6. Moderate to severe traumatic brain injury (mental status change or loss of consciousness>30 min; Glasgow Coma Scale \<13; post-traumatic amnesia>24hours; visible lesion on CT/MRI brain scan).
  7. Active alcohol/illicit substance use disorder within 6 months of initial assessment; presence of illicit drugs by positive urine toxicology.
  8. For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments within 3 months of screening, or inability/ unwillingness to use a medically accepted method during the study.
  9. Imminent risk of suicidal/homicidal ideation and/or behavior with intent and/or plan
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ketamine and PE

    ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.

    Drug: ketamine-enhanced prolonged exposure

Interventions

  • Drugketamine-enhanced prolonged exposure

    Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.

06

What researchers measure

Primary outcomes

  1. Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms

    The overall severity of PTSD symptoms would be measured by the mean change in the Past Month (current) total scores on the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5) from baseline to post-treatment (10 weeks). The CAPS-5 is a structured interview with higher values representing worse outcomes. The CAPS-5 total symptom severity score ranges from 0 to 80 and it is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms.

    Time frame: 10 weeks

Secondary outcomes

  1. Change in Severity of Depressive Symptoms

    Total score on the Montgomery- Åsberg Depression Rating Scale , a semi- structured 10-item scale. Range 0-60. Higher values represent worse outcomes. The total score is obtained by summing the severity score of each item.

    Time frame: 10 weeks

  2. Change in PTSD Symptoms for DSM-5

    The PTSD Checklist for DSM-5 (PCL5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Range from 0-80. Higher values represent worse outcomes.

    Time frame: 10 weeks

07

Results

Posted Mar 22, 2021

Participant flow

Participant flow — Overall Study
MilestoneKetamine and Prolonged Exposure
Started12
Completed10
Not completed2

Outcome measures

PrimaryChange in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms

The overall severity of PTSD symptoms would be measured by the mean change in the Past Month (current) total scores on the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5) from baseline to post-treatment (10 weeks). The CAPS-5 is a structured interview with higher values representing worse outcomes. The CAPS-5 total symptom severity score ranges from 0 to 80 and it is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms.

Time frame:
10 weeks
Reported as:
Mean · units on a scale
Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms
units on a scaleKetamine and Prolonged Exposure
Change in Severity of Post-traumatic Stress Disorder (PTSD) Symptoms15.3 (7.3 to 23.2)
SecondaryChange in Severity of Depressive Symptoms

Total score on the Montgomery- Åsberg Depression Rating Scale , a semi- structured 10-item scale. Range 0-60. Higher values represent worse outcomes. The total score is obtained by summing the severity score of each item.

Time frame:
10 weeks
Reported as:
Mean · units on a scale
Change in Severity of Depressive Symptoms
units on a scaleKetamine and Prolonged Exposure
Change in Severity of Depressive Symptoms11.5 (6.1 to 16.9)
SecondaryChange in PTSD Symptoms for DSM-5

The PTSD Checklist for DSM-5 (PCL5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Range from 0-80. Higher values represent worse outcomes.

Time frame:
10 weeks
Reported as:
Mean · score on a scale
Change in PTSD Symptoms for DSM-5
score on a scaleKetamine and Prolonged Exposure
Change in PTSD Symptoms for DSM-530.8 (20.1 to 41.4)

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketamine and Prolonged Exposure0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventKetamine and Prolonged Exposure
high blood pressureCardiac disorders3/10
nauseaGastrointestinal disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ketamine and Prolonged Exposure
Mean45.1 ± 14.9
Sex: Female, Male
Sex: Female, Male(Participants)Ketamine and Prolonged Exposure
Female3
Male7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ketamine and Prolonged Exposure
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Ketamine and Prolonged Exposure
United States10
Post-traumatic Stress Disorder Check List DSM-5
Post-traumatic Stress Disorder Check List DSM-5(units on a scale)Ketamine and Prolonged Exposure
Mean56.3 ± 9.8
Montgomery-Åsberg Depression rating Scale
Montgomery-Åsberg Depression rating Scale(units on a scale)Ketamine and Prolonged Exposure
Mean25.0 ± 6.0
08

Study locations

1 site
  • Minneapolis VA Medical Center
    Minneapolis, Minnesota 55417, United States
09

References and documents

Publications

  • Shiroma PR, Thuras P, Wels J, Erbes C, Kehle-Forbes S, Polusny M. A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine Combined With Prolonged Exposure Therapy Among Veterans With Posttraumatic Stress Disorder. J Clin Psychiatry. 2020 Nov 10;81(6):20l13406. doi: 10.4088/JCP.20l13406. No abstract available. PubMed 33176074 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Nov 2019, 7 months.

Results were first posted in Mar 2021, 1 year 4 months after primary completion.

Of 17 phase 1/2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2019
First posted
May 23, 2019
StartActual
Apr 3, 2019
Primary completionActual
Nov 18, 2019
CompletionActual
Dec 4, 2019
Results first posted
Mar 22, 2021
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and index terms
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03960658
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Responsible party
Paulo Shiroma (Clinical Investigator, Minneapolis Veterans Affairs Medical Center) — Principal investigator
First posted
May 23, 2019
Start date
Apr 3, 2019
Primary completion
Nov 18, 2019
Completion
Dec 4, 2019
Results posted
Mar 22, 2021
Last update
Oct 14, 2026

Study contacts

Paulo R Shiroma, MD
principal investigator · Minneapolis Veterans Affairs Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion